Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
Status:
Recruiting
Trial end date:
2020-12-20
Target enrollment:
Participant gender:
Summary
We hypothesize that Dapagliflozin could improve the diuretic response in diabetic patients
with acute decompensated heart failure owing to its diuretic effect in addition to
improvement of blood glucose level without remarkable effect on kidney function or
electrolytes.